Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative recovery and multi-organ protection after major thoracic and abdominal surgery
ChiCTR2400080286Phase 4Not yet recruiting
- Sponsor
- Taizhou Municipal Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postoperative delirium (POD), Delayed postoperative recovery (DPR), Postoperative Organ Dysfunction (POD) and 1 more (2 arms), sponsored by Taizhou Municipal Hospital. Primary endpoints: Postoperative delirium incidence (POD) and Quality of recovery-15 score (QoR-15). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)Delayed postoperative recovery (DPR)Postoperative Organ Dysfunction (POD)Brain function impairment
Beyond the preview
Go deeper on ChiCTR2400080286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080286.